Archived explainer. For the current picture see today's TXG page.
Why Is 10X GENOMICS INC A (TXG) Stock Up Today?
By the Top Tier Newswire AI Desk · August 19, 2026 at 9:50 AM ET · reviewed against 1 wire stories
10X GENOMICS INC A (TXG) is up +8.63% in the latest session. Our newswire has captured 1 story on TXG across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 67/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
10X Genomics Inc. (TXG) shares rose 8.63% to $60.43 in early trading on August 19. The move followed a report of strong early orders for its new Atera platform and a recent earnings report that included a $1.6 million settlement payment from Takara. The stock opened with a modest 0.7% gap up and climbed steadily to a session high of $61.25 before settling near $60.42.
What Happened
On August 6, 10X Genomics reported second-quarter revenue of $151 million, which included a $1.6 million settlement payment from Takara. Adjusting for that payment, revenue grew 3% year-over-year to $149.4 million. The company has seen strong early orders for its new Atera platform, which has generated optimism among investors. The stock opened at $56.00 and traded higher throughout the session, reaching a high of $61.25. The move comes amid several recent analyst updates, including price target increases from Stephens & Co., Piper Sandler, Canaccord Genuity, Citigroup, and Morgan Stanley.
What The Data Shows
The stock’s intraday session showed a volume of 0.6 million shares, which is 0.2 times the 3-month daily average. The stock has a market cap of $7.6 billion but remains unprofitable with an EPS of -0.59 over the trailing twelve months. Revenue has declined 4.3% year-to-date, and the stock has a beta of 2.04, indicating high volatility. On August 19, the stock printed one fresh 52-week low and three fresh 52-week highs. Recent insider transactions show 7 sales totaling $4.2 million over the last 90 days, with the most recent sale reported on August 17.
What To Watch
The stock is currently trading near its 52-week high of $60.69. Investors may look for further details on the Atera platform’s performance and any upcoming product launches. Analyst coverage remains mixed, with price targets ranging from $40 to $65.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TXG · Aug 19 session (5-min) · +12.96% vs prior close · updated 8:57 PM ETAI sentiment, last 36h · averaged over 1 story · 67/100 bullish
The headlines behind the move
Story flow · 1 story on the wire, last 36h · hover or tap a dot for the headline
26d agoYahoo FinanceBULLISH 67Product/PR
10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform
On August 6, 10x Genomics (NASDAQ:TXG) reported second-quarter revenue of $151 million, boosted by a $1.6 million settlement payment from Takara. Strip that out and revenue grew just 3% year-over-year to $149.4 million, a modest number next to the real headline of the quarter: a brand-new instrument platform called Atera, where booked orders have exceeded […]
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →